This page aggregates ALZN's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
ALZN run-up, measured
Computed from this stock's own daily closing prices, on the same T-120 basis as the run-up study: the baseline is the close 120 trading sessions before the eve of the decision. These are measurements of what already happened, not predictions.
ALZN's past FDA decisions (n=1)
Decision
Outcome
T-120 to eve
T-120 to peak
2023-11-13
APPROVAL
-81.3%
+48.7%
With only one decision on record, no median is shown: an average of 1 event would not be a meaningful statistic. The individual figures above are exact. For a statistical base see the run-up study, built on 1,855 decisions.
Common questions
When is the next FDA decision or readout for Alzamend Neuro, Inc. (ALZN)?
Q3 2026. The next catalyst for Alzamend Neuro, Inc. is AL001 Phase II topline (bipolar disorder) (readout). That date is known to the quarter only. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.
How do stocks like ALZN move into an FDA decision?
We have no measured history for ALZN itself. Across the whole study of 1,855 FDA decisions, the median stock rose 17.9% at its best point in the 120 trading days before the decision, but was only 2.2% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
Where does this ALZN data come from?
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.